154 related articles for article (PubMed ID: 19384688)
1. Between-arm comparisons in randomized Phase II trials.
Jung SH; George SL
J Biopharm Stat; 2009; 19(3):456-68. PubMed ID: 19384688
[TBL] [Abstract][Full Text] [Related]
2. Randomized phase II clinical trials.
Jung SH; Sargent DJ
J Biopharm Stat; 2014; 24(4):802-16. PubMed ID: 24697589
[TBL] [Abstract][Full Text] [Related]
3. Sample size computation in phase II designs combining the A'Hern design and the Sargent and Goldberg design.
Neven A; Mauer M; Hasan B; Sylvester R; Collette L
J Biopharm Stat; 2020 Mar; 30(2):305-321. PubMed ID: 31331234
[TBL] [Abstract][Full Text] [Related]
4. Curtailed two-stage design for comparing two arms in randomized phase II clinical trials.
Chen CM; Chi Y; Chang HM
J Biopharm Stat; 2018; 28(5):939-950. PubMed ID: 29355457
[TBL] [Abstract][Full Text] [Related]
5. Selecting promising treatments in randomized Phase II cancer trials with an active control.
Cheung YK
J Biopharm Stat; 2009; 19(3):494-508. PubMed ID: 19384691
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase II trials with a prospective control.
Jung SH
Stat Med; 2008 Feb; 27(4):568-83. PubMed ID: 17573688
[TBL] [Abstract][Full Text] [Related]
7. Optimal designs for two-arm, phase II clinical trial design with multiple constraints.
Mayo MS; Mahnken JD; Soong SJ
J Biopharm Stat; 2010 Jan; 20(1):106-24. PubMed ID: 20077252
[TBL] [Abstract][Full Text] [Related]
8. A modification of Simon's optimal design for phase II trials when the criterion is median sample size.
Hanfelt JJ; Slack RS; Gehan EA
Control Clin Trials; 1999 Dec; 20(6):555-66. PubMed ID: 10588296
[TBL] [Abstract][Full Text] [Related]
9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
10. Screened selection design for randomised phase II oncology trials: an example in chronic lymphocytic leukaemia.
Yap C; Pettitt A; Billingham L
BMC Med Res Methodol; 2013 Jul; 13():87. PubMed ID: 23819695
[TBL] [Abstract][Full Text] [Related]
11. Modified Simon's minimax and optimal two-stage designs for single-arm phase II cancer clinical trials.
Kim J; Schell MJ
Oncotarget; 2019 Jul; 10(42):4255-4261. PubMed ID: 31303960
[TBL] [Abstract][Full Text] [Related]
12. Comparing an experimental agent to a standard agent: relative merits of a one-arm or randomized two-arm Phase II design.
Taylor JM; Braun TM; Li Z
Clin Trials; 2006; 3(4):335-48. PubMed ID: 17060208
[TBL] [Abstract][Full Text] [Related]
13. Minimax and admissible adaptive two-stage designs in phase II clinical trials.
Shan G; Zhang H; Jiang T
BMC Med Res Methodol; 2016 Aug; 16():90. PubMed ID: 27485595
[TBL] [Abstract][Full Text] [Related]
14. Leveraging historical data into oncology development programs: Two case studies of phase 2 Bayesian augmented control trial designs.
Smith CL; Thomas Z; Enas N; Thorn K; Lahn M; Benhadji K; Cleverly A
Pharm Stat; 2020 May; 19(3):276-290. PubMed ID: 31903699
[TBL] [Abstract][Full Text] [Related]
15. A Review of Perspectives on the Use of Randomization in Phase II Oncology Trials.
Grayling MJ; Dimairo M; Mander AP; Jaki TF
J Natl Cancer Inst; 2019 Dec; 111(12):1255-1262. PubMed ID: 31218346
[TBL] [Abstract][Full Text] [Related]
16. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
[TBL] [Abstract][Full Text] [Related]
17. Phase II cancer clinical trials with heterogeneous patient populations.
Jung SH; Chang MN; Kang SJ
J Biopharm Stat; 2012; 22(2):312-28. PubMed ID: 22251176
[TBL] [Abstract][Full Text] [Related]
18. Comparison of error rates in single-arm versus randomized phase II cancer clinical trials.
Tang H; Foster NR; Grothey A; Ansell SM; Goldberg RM; Sargent DJ
J Clin Oncol; 2010 Apr; 28(11):1936-41. PubMed ID: 20212253
[TBL] [Abstract][Full Text] [Related]
19. A new adaptive design based on Simon's two-stage optimal design for phase II clinical trials.
Jin H; Wei Z
Contemp Clin Trials; 2012 Nov; 33(6):1255-60. PubMed ID: 22772088
[TBL] [Abstract][Full Text] [Related]
20. Many-to-one comparisons after safety selection in multi-arm clinical trials.
Hlavin G; Hampson LV; Koenig F
PLoS One; 2017; 12(6):e0180131. PubMed ID: 28651023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
